GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Nov 13, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on November 13, 2025, that it has purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker executing share purchases
- November 2025 (date) — Reporting period for the transaction
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares during the month of November 2025.
Who is acting as the broker for GSK's share repurchases?
BNP Paribas SA is acting as the broker for GSK plc's share repurchases.
Does the filing specify the number of shares GSK purchased?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What is the principal executive office address of GSK plc?
The principal executive office address of GSK plc is 79 New Oxford Street, London, WC1A 1DG.
Has GSK plc changed its name recently?
Yes, GSK plc was formerly known as GlaxoSmithKline PLC, with a name change date of January 5, 2001, and also formerly known as GSK PLC with a name change date of May 16, 2022.
Filing Stats: 3,064 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-11-13 06:41:05
Filing Documents
- a3150h.htm (6-K) — 1797KB
- 0001654954-25-012955.txt ( ) — 1798KB
From the Filing
IN OWN SHARES a3150h   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of November 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .         Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase: 12 November 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 167,000 Lowest price paid per share (GBp): 1,805.50p Highest price paid per share (GBp): 1,827.00p Volume-weighted average price paid per share (GBp): 1,813.49p     The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 8,663,000 ordinary shares.   Following the above purchase, the Company will hold 256,127,844 ordinary shares in treasury and have 4,059,300,530 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,059,300,530. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.31 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases Shares purchased:     GSK plc (ISIN: GB00BN7SWP63) Date of purchases:      12 November 2025 Investment firm:         BNP Paribas SA      Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   21,369   1,827.00p   1,806.00p   1,812.80p   CHIX   52,951   1,827.00p   1,805.50p   1,813.50p   XLON   92,680   1,827.00p   1,805.50p   1,813.64p       Individual transactions: Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   325   1827.0   CHIX   12-Nov-2025   08:00:30   20251112152857476   93   1827.0   CHIX   12-Nov-2025   08:00:30   20251112152857478   65   1827.0   BATE   12-Nov-2025   08:00:30   20251112152857480   206   1827.0   XLON   12-Nov-2025